A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 4, 2014, Pages 705-712

  Macdougall, Iain C ^a   Strauss, William E ^b   McLaughlin, Justin ^b   Li, Zhu ^b   Dellanna, Frank ^c   Hertel, Joachim ^d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b AMAG PHARMACEUTICALS INC   (United States)

^c Nephrology Center Karlstr   (Germany)

^d Greenville Kidney Care LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; DIPHENHYDRAMINE; FERUMOXYTOL; HYDROCORTISONE; IRON SACCHARATE; ANTIANEMIC AGENT; BIOLOGICAL MARKER; FERRIC ION; FERRIC OXIDE, SACCHARATED; HEMOGLOBIN; MAGNETITE; SACCHARIC ACID;

ADULT; ANAPHYLAXIS; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; GLOMERULUS FILTRATION RATE; GOUT; HEADACHE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERSENSITIVITY; HYPOGLYCEMIA; HYPOTENSION; INJECTION SITE PAIN; INTENTION TO TREAT ANALYSIS; IRON DEFICIENCY ANEMIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; OPEN STUDY; PAROSMIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSITIVITY ANALYSIS; TRANSFERRIN BLOOD LEVEL; URINARY TRACT INFECTION; VITAL SIGN; AGED; ANEMIA, IRON-DEFICIENCY; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; REGRESSION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; TIME; TREATMENT OUTCOME;

AGED; ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; FEMALE; FERRIC COMPOUNDS; FERROSOFERRIC OXIDE; GLUCARIC ACID; HEMATINICS; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904054374     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05320513     Document Type: Article

References (18)

1. Fishbane S, Pollack S, Feldman HI, Joffe MM: Iron indicesinchronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004. Clin J Am Soc Nephrol 4: 57–61, 2009
2. Valderrábano F, Hörl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP: Pre-dialysis survey on anaemia management. Nephrol Dial Transplant 18: 89–100, 2003
3. Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT, Pereira BJ: Anemia: An early complication of chronic renal insufficiency. Am J Kidney Dis 38: 803–812, 2001
4. KDOQI; National Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47[5 Suppl 3]: S1– S146, 2006
5. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2: 279–331, 2012
6. American Regent Laboratories, Inc.: Venofer (Package Insert), Shirley, NY, American Regent Laboratories, Inc., 2009 Ferrlecit (Package Insert), Bridgewater, NJ, 2011
7. Ferrlecit (Package Insert), Bridgewater, NJ, 2011
8. NKF-KDOQI: NKF-KDOQI Clinical Practice Guidelines for Vascular Access. Am J Kidney Dis 48[Suppl 1]: S176–S247, 2006
9. American Regent Laboratories, Inc.: Dexferrum (Package Insert), Shirley, NY, American Regent Laboratories, Inc., 2009
10. INFed (Package Insert), Morristown, NJ, 2006
11. Sav T, Tokgoz B, Sipahioglu MH, Deveci M, Sari I, Oymak O, Utas C: Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 29: 423–426, 2007
12. Anirban G, Kohli HS, Jha V, Gupta KL, Sakhuja V: The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail 30: 629–638, 2008
13. Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM: A randomized, controlled parallel-group trial on efficacy and safetyof iron sucrose (Venofer)vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 16: 1239–1244, 2001
14. Sheashaa H, El-Husseini A, Sabry A, Hassan N, Salem A, Khalil A, El-Agroudy A, Sobh M: Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: A comparative study between iron saccharate and gluconate. Nephron Clin Pract 99: c97–c101, 2005
15. US National Institutes of Health: Clinical Trials.Gov, 2005. Available at: http://clinicaltrials.gov/ct/show/NCT00255424?or-der=1. Accessed May 3, 2013
16. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ: Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19: 1599–1605, 2008
17. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ: Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 4: 386–393, 2009
18. AMAG Pharmaceuticals, Inc.: A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared with Oral Iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients Not on Dialysis. ClinicalTrials.gov, 2007. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00255437. Accessed May 3, 2012